14.11.2020 17:00:41

J&J, U.S. Expand Agreement To Support Next Phase Of COVID-19 Vaccine R&D

(RTTNews) - Johnson & Johnson (JNJ) said Saturday that the company and the U.S. Department of Health & Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development.

As per the agreement, the company's Janssen will commit about $604 million and the U.S. Department of Health & Human Services' the Biomedical Advanced Research and Development Authority or BARDA will commit about $454 million to support the ongoing Phase 3 ENSEMBLE trial.

The trial is evaluating Janssen's investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.

Analysen zu Johnson & Johnsonmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Johnson & Johnson 138,70 -0,47% Johnson & Johnson